Review
doi: 10.1016/j.idc.2009.06.010.
Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin
Affiliations
- PMID: 19909893
- DOI: 10.1016/j.idc.2009.06.010
Item in Clipboard
Review
Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin
Infect Dis Clin North Am.
2009 Dec.
Abstract
An overview of the mechanism of action, dosing, clinical indications, and toxicities of the glycopeptide vancomycin is provided. The emerging gram-positive bacterial resistance to antimicrobials and its mechanisms are reviewed. Strategies to control this emergence of resistance are expected to be proposed. Newer antimicrobial agents that have activity against vancomycin-resistant organisms are now available and play a critical role in the treatment of life-threatening infections.
Republished in
-
Antibiotics for gram-positive bacterial infection: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, telavancin, and ceftaroline.Med Clin North Am. 2011 Jul;95(4):723-42, vii. doi: 10.1016/j.mcna.2011.03.011. Med Clin North Am. 2011. PMID: 21679789
Similar articles
-
Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.Infect Dis Clin North Am. 2004 Sep;18(3):651-68, x. doi: 10.1016/j.idc.2004.04.014. Infect Dis Clin North Am. 2004. PMID: 15308280 Review.
-
Antibiotics for gram-positive bacterial infection: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, telavancin, and ceftaroline.Med Clin North Am. 2011 Jul;95(4):723-42, vii. doi: 10.1016/j.mcna.2011.03.011. Med Clin North Am. 2011. PMID: 21679789
-
A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Pharmacotherapy. 2010 Jan;30(1):80-94. doi: 10.1592/phco.30.1.80. Pharmacotherapy. 2010. PMID: 20030476 Review.
-
Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria.J Infect. 2009 Sep;59 Suppl 1:S17-24. doi: 10.1016/S0163-4453(09)60004-9. J Infect. 2009. PMID: 19766885 Review.
-
Current and new antimicrobial agents.Am Heart J. 2004 Apr;147(4):587-92. doi: 10.1016/j.ahj.2003.06.006. Am Heart J. 2004. PMID: 15077072
Cited by
-
Endophthalmitis caused by gram-positive bacteria resistant to vancomycin: Clinical settings, causative organisms, antimicrobial susceptibilities, and treatment outcomes.Am J Ophthalmol Case Rep. 2018 Feb 28;10:211-214. doi: 10.1016/j.ajoc.2018.02.030. eCollection 2018 Jun. Am J Ophthalmol Case Rep. 2018. PMID: 29552670 Free PMC article.
-
A comparison of different antibiotic regimens for the treatment of infective endocarditis.Cochrane Database Syst Rev. 2020 May 14;5(5):CD009880. doi: 10.1002/14651858.CD009880.pub3. Cochrane Database Syst Rev. 2020. PMID: 32407558 Free PMC article.
-
The potential risk factors of nephrotoxicity during vancomycin therapy in Chinese adult patients.Eur J Hosp Pharm. 2021 Nov;28(Suppl 2):e51-e55. doi: 10.1136/ejhpharm-2020-002261. Epub 2020 Jun 10. Eur J Hosp Pharm. 2021. PMID: 32522809 Free PMC article.
-
Endophthalmitis caused by Gram-positive organisms with reduced vancomycin susceptibility: literature review and options for treatment.Br J Ophthalmol. 2016 Apr;100(4):446-52. doi: 10.1136/bjophthalmol-2015-307722. Epub 2015 Dec 23. Br J Ophthalmol. 2016. PMID: 26701686 Free PMC article. Review.
-
Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review.Int J Clin Pharm. 2013 Oct;35(5):697-703. doi: 10.1007/s11096-013-9825-5. Epub 2013 Jul 27. Int J Clin Pharm. 2013. PMID: 23893061 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
